# Ocugen (OCGN) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/OCGN
## Company Profile
- Ticker: OCGN
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Gene Therapy, Inherited Retinal Disease Gene Therapy, Ophthalmology
## Stock Data
- Close: 1.36 USD
- Market cap: 453619287.04 USD
- Last updated: 2026-09-04
## Business Overview
Ocugen is a biotechnology company focused on ophthalmology, gene therapy, and vaccine-related programs. Its story has been shaped by a mix of platform ambition and strategic pivots.
## Why The Stock Is Moving

As of Sep 4, 2026, OCGN closed up 0.74% at $1.36. No new same-company headline was identified in the current news window.

## Geographic Base

Headquartered in the United States and listed on NASDAQ, Ocugen sits in specialty biotechnology.

## Business Model

The company depends on clinical development, partnership progress, and the ability to create value across a narrow set of programs.

## Landscape Position

Ocugen is a high-uncertainty biotech name whose valuation is driven by strategy and development milestones.

## Future Catalysts

- Ocugen’s catalysts are the gene-therapy and biologics pipeline, with any update on retinal or vaccine-related work shaping the next leg. The market will want a clearer human-data path before assigning more value.

## Recent News
- 2026-09-01 11:02 EST — [Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration](https://biopharmsignal.com/news/OCGN/ocugen-announces-first-patient-dosed-in-phase-3-registrational-trial-of-ocu410-m-5728a6d6) — Source: Ocugen
- 2026-08-25 11:02 EST — [Ocugen to Participate in Upcoming September Investor and Industry Conferences](https://biopharmsignal.com/news/OCGN/ocugen-to-participate-in-upcoming-september-investor-and-industry-conferences-16cf3119) — Source: Ocugen
- 2026-08-06 11:02 EST — [Ocugen Provides Business Update with Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/OCGN/ocugen-provides-business-update-with-second-quarter-2026-financial-results-5feb3ea6) — Source: Ocugen
- 2026-07-31 11:02 EST — [Ocugen to Participate in Upcoming August Investor Conferences](https://biopharmsignal.com/news/OCGN/ocugen-to-participate-in-upcoming-august-investor-conferences-2ecb8549) — Source: Ocugen
- 2026-07-29 11:01 EST — [Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration](https://biopharmsignal.com/news/OCGN/ocugen-announces-that-the-u-s-food-and-drug-administration-has-granted-ocu410-re-ce6aa687) — Source: Ocugen